Our data suggest that PTCL patients with activating STAT5 mutations could benefit from STAT5 inhibitors either as mono-therapy or in combination with additional therapeutic strategies to provide more efficacious, less toxic treatment. The gene discussed is STAT5A; the disease is mature T-cell and NK-cell non-Hodgkin lymphoma.